These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 23911186)
21. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Brunton S Diabetes Technol Ther; 2008 Aug; 10(4):247-56. PubMed ID: 18715198 [TBL] [Abstract][Full Text] [Related]
22. Engineering study comparing injection force and dose accuracy between two prefilled insulin injection pens. Ignaut DA; Opincar MR; Clark PE; Palaisa MK; Lenox SM Curr Med Res Opin; 2009 Dec; 25(12):2829-33. PubMed ID: 19916727 [TBL] [Abstract][Full Text] [Related]
23. Validation of the SoloSTAR insulin pen. Schwartz S; Vlajnic A Diabetes Technol Ther; 2008 Oct; 10(5):351-7. PubMed ID: 18715210 [TBL] [Abstract][Full Text] [Related]
24. FlexTouch® for the delivery of insulin: technical attributes and perception among patients and healthcare professionals. Bailey T; Campos C Expert Rev Med Devices; 2012 May; 9(3):209-17. PubMed ID: 22471783 [TBL] [Abstract][Full Text] [Related]
25. Insulin delivery with FlexPen: dose accuracy, patient preference and adherence. Pfützner A; Asakura T; Sommavilla B; Lee W Expert Opin Drug Deliv; 2008 Aug; 5(8):915-25. PubMed ID: 18713000 [TBL] [Abstract][Full Text] [Related]
26. Dose accuracy of new versus used Novopen 4 insulin pens. Yucel H; Taks M; Menheere P; Grouls R; Bravenboer B Diabetes Technol Ther; 2012 Sep; 14(9):810-2. PubMed ID: 22866889 [TBL] [Abstract][Full Text] [Related]
27. Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes. Garg S; Kelly WC; Garg S Expert Rev Med Devices; 2008 Mar; 5(2):113-23. PubMed ID: 18331174 [TBL] [Abstract][Full Text] [Related]
28. Development of the SoloSTAR insulin pen device: design verification and validation. Bode A Expert Opin Drug Deliv; 2009 Jan; 6(1):103-12. PubMed ID: 19236211 [TBL] [Abstract][Full Text] [Related]
29. Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes. Warren ML; Brod M; Håkan-Bloch J; Sparre T; Chaykin LB Curr Med Res Opin; 2019 Sep; 35(9):1623-1629. PubMed ID: 30974973 [No Abstract] [Full Text] [Related]
30. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Nadeau DA; Campos C; Niemeyer M; Bailey T Curr Med Res Opin; 2012 Jan; 28(1):3-13. PubMed ID: 22114905 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the dose accuracy of prefilled insulin pens. Weise A; Pfützner JW; Borig J; Pfützner AM; Safinowski M; Hänel H; Musholt PB; Pfützner A J Diabetes Sci Technol; 2009 Jan; 3(1):149-53. PubMed ID: 20046658 [TBL] [Abstract][Full Text] [Related]
32. Consensus on Choice of Insulin Pen Devices in Routine Clinical Practice in India. Gupta A; Phatak S; Rao YS; Ramesh J; Sanyal D Diabetes Technol Ther; 2020 Oct; 22(10):777-786. PubMed ID: 32233934 [TBL] [Abstract][Full Text] [Related]
33. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Oyer D; Narendran P; Qvist M; Niemeyer M; Nadeau DA Expert Opin Drug Deliv; 2011 Oct; 8(10):1259-69. PubMed ID: 21905942 [TBL] [Abstract][Full Text] [Related]
34. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750 [TBL] [Abstract][Full Text] [Related]
35. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Perfetti R Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S79-85. PubMed ID: 20515312 [TBL] [Abstract][Full Text] [Related]
36. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Rubin RR; Peyrot M Diabetes Care; 2004 Oct; 27(10):2495-7. PubMed ID: 15451924 [No Abstract] [Full Text] [Related]
37. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Korytkowski M; Bell D; Jacobsen C; Suwannasari R; Clin Ther; 2003 Nov; 25(11):2836-48. PubMed ID: 14693308 [TBL] [Abstract][Full Text] [Related]
38. A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes. Hancu N; Czupryniak L; Genestin E; Sourij H J Diabetes Sci Technol; 2011 Sep; 5(5):1224-34. PubMed ID: 22027323 [TBL] [Abstract][Full Text] [Related]
39. FlexTouch: An Insulin Pen-Injector with a Low Activation Force Across Different Insulin Formulations, Needle Technologies, and Temperature Conditions. Gudiksen N; Hofstätter T; Rønn BB; Sparre T Diabetes Technol Ther; 2017 Oct; 19(10):603-607. PubMed ID: 28704062 [TBL] [Abstract][Full Text] [Related]
40. Analysis of patient satisfaction with a prefilled insulin injection device in patients with type 1 and type 2 diabetes. Siegmund T J Diabetes Sci Technol; 2011 Sep; 5(5):1235-7. PubMed ID: 22027324 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]